bevictor伟德官网

2024年5月10日 钟筱波:表观遗传与体内药物代谢个体差异


报告题目:表观遗传与体内药物代谢个体差异

报 告 人:钟筱波 教授

主 持 人:王   昕 教授

报告时间:2024年5月10日下午2:00 - 3:30

报告地点:闵行校区bevictor伟德官网534会议室


报告人简介:

钟筱波博士是美国康涅狄格大学(University of Connecticut)药学院药学系教授和药理学与毒理学研究室主任。他曾获得北京大学生物学学士学位,荷兰瓦赫宁根大学生物技术硕士学位与分子生物学博士学位,并曾在美国耶鲁大学医学院遗传系接受博士后培训。钟博士在2012年加入康涅狄格大学之前是美国堪萨斯大学医学中心的助理教授和副教授。他目前是美国药理学会(ASPET),国际异源物代谢研究学会(ISSX),美中药协(SAPA),华人生物学家协会(CBIS),美洲华人生物科学学会会员。他曾担任美国药理学会药物代谢专业委员会(DDMD of ASPET)的执委(2009-2012)和主席(2021-2022)。他目前担任6种期刊(Drug Metabolism and Disposition, Noncoding RNA, Nuclear Receptor Research, Frontiers, Journal of Drug Metabolism and Toxicology, Acta Pharmaceutica Sinica B)的编委,并担任Drug Metabolism and Disposition的副主编和综述编辑以及Non-coding RNA和Frontiers in Pharmacology的副主编,并为六十多种学术期刊做过审稿人。他还担任美国国立卫生研究院(NIH)多个基金的特约评审员。在过去近二十年里,他先后获得美国国立卫生研究院多项R35、R01和P20的经费资 助。钟教授已在药物代谢、发育药理学、药物遗传学、药物表观遗传学和个体化用药,小核酸药物研发和临床应用等研究领域发表100多篇研究论文,为康涅狄格大学药学院本科和研究生主讲《药物作用原理》和《药物基因组学与个性化医疗》, 并参与《药物研发》、《药理学》、《毒理学》、《药物安全评价原理》等核心课程的授课。


报告简介:

Significant interindividual and intraindividual variations on cytochrome P450 (CYP)-mediated drug metabolism exist in the general population globally. Genetic polymorphisms are one of the major contribution factors for interindividual variations, but epigenetic mechanisms mainly contribute to intraindividual variations, including DNA methylation, histone modifications, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs). The presentation will provide advanced knowledge in the last decade on contributions of epigenetic mechanisms to intraindividual variations on CYP-mediated drug metabolism in several situations, including (1) ontogeny, the developmental changes of CYP expression in individuals from neonates to adults; (2) increased activities of CYP enzymes induced by drug treatment; (3) increased activities of CYP enzymes in adult ages induced by drug treatment at neonate ages; and (4) decreased activities of CYP enzymes in individuals with drug-induced liver injury (DILI). Furthermore, current challenges, knowledge gaps, and future perspective of the epigenetic mechanisms in development of CYP pharmacoepigenetics will be discussed. In conclusion, epigenetic mechanisms have been proven to contribute to intraindividual variations of drug metabolism mediated by CYP enzymes in age development, drug induction, and DILI conditions. The knowledge has helped understanding how intraindividual variation are generated. Future studies are needed to develop CYP-based pharmacoepigenetics to guide clinical applications for precision medicine with improved therapeutic efficacy and reduced risk of adverse drug reactions (ADRs) and toxicity.


5.10 王昕 学术海报.jpg